Market Access News | pharmaphorum

News

Outlook finally claims FDA approval for AMD drug

After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.

News

Re-rostered FDA committee backs peptide compounding

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.

News

EU clears AZ's SERD camizestrant, as FDA review drags on

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

As patents expire, fampridine is cleared for NHS use in MS

Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.

News

Takeda gets first OK for orexin narcolepsy drug, in China

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.

Outlook finally claims FDA approval for AMD drug

Re-rostered FDA committee backs peptide compounding

EU clears AZ's SERD camizestrant, as FDA review drags on

Nuvalent buy delivers new cancer approval for GSK

As patents expire, fampridine is cleared for NHS use in MS

Takeda gets first OK for orexin narcolepsy drug, in China

Sandoz says it is entering "golden decade" in biosimilars

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks